Skip to main content
. 2017 Apr 27;1(3):195–202. doi: 10.1007/s41669-017-0024-5

Table 5.

Treatment specific risks and costs

Annual risk of grade 3/4 toxicities by regimen Source Anemia (%) Febrile neutropenia (%) Leukopenia (%) Thrombocytopenia (%) Infection (%) Costs
Bendamustine + rituximab [24] 5.8402 0.0000 5.1316 9.3947 2.6842 ¥ 26,614
Fludarabine + cyclophosphamide + rituximab [25] 6.8571 6.8571 0.0000 6.2857 2.8671 ¥ 23,978
Ofatumumab [10] 10.8148 3.8518 0.0000 6.2222 10.0741 ¥ 29,964
Ibrutinib [10] 2.1677 1.5871 1.0065 2.1677 7.7419 ¥ 16,695